



FOR IMMEDIATE RELEASE

IMRIS ANNOUNCES \$40 MILLION INITIAL PUBLIC OFFERING

**/NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR
DISSEMINATION IN THE UNITED STATES/**

WINNIPEG, October 26 - IMRIS Inc. ("IMRIS") announced today that it has filed its final prospectus and entered into an underwriting agreement with a syndicate of underwriters led by RBC Capital Markets and including BMO Capital Markets, TD Securities Inc., Canaccord Capital Corporation and GMP Securities L.P., in relation to its \$40,000,000 initial public offering of common shares at a price of \$6.00 per common share. IMRIS has also granted to the underwriters an option, exercisable until 30 days following closing of the offering, to acquire an additional 1,000,000 common shares on the same terms and conditions to cover over-allotments, if any, and for market stabilization purposes. It is anticipated that closing of the offering will occur on November 2, 2007 and that the common shares will begin trading that day on the TSX under the symbol "IM".

The securities offered have not been, and will not be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or any applicable exemption from the registration requirement of such Act. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

About IMRIS

IMRIS is a global leader in the supply of fully-integrated, intra-operative imaging solutions designed to assist in the treatment of disease and to measurably improve patient outcomes. Our flagship product, IMRISneuro, is a neurosurgical MR imaging system which provides near real-time, high-resolution MR imaging with integrated data management and display systems. The combination of high resolution MR images, improved patient safety, enhanced surgical efficiency, a fully integrated operating room, and the potential for increased financial viability contributes to a surgical imaging offering that we believe has not previously been available to medical teams and their patients. For more information about IMRIS please visit the company's website at www.imris.com

Forward-Looking Statements

This press release may contain or refer to forward-looking information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on

management's reasonable assumptions, there can be no assurance that actual results will be consistent with such statements. These forward-looking statements are made as of the date hereof and we assume no responsibility to update or revise them to reflect new events or circumstances.

For further information:

Susan McLeod, Manager, Marketing Communications, (204) 480-7070,

smcleod@imris.com

CO: IMRIS Inc.